Valuation : Roche Holding AG

Market Cap 279B 344B 297B 255B 476B 32,470B 479B 3,307B 1,283B 16,601B 1,291B 1,263B 54,534B P/E 2026 *
19.5x
P/E 2027 * 17.3x
Enterprise Value 290B 357B 308B 264B 494B 33,733B 498B 3,436B 1,333B 17,247B 1,341B 1,312B 56,655B EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.33x
Free-Float
88.78%
Yield 2026 *
2.86%
Yield 2027 * 2.93%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 344B
-0.25%-2.47%+57.79%+108.23% 1,034B
+0.92%+1.93%+54.56%+71.49% 663B
+0.35%-0.45%+23.50%+76.60% 462B
+2.39%-0.93%+33.80%+39.96% 344B
+0.54%+6.31%+28.54%+48.83% 307B
+2.12%+1.24%+0.44%+14.72% 251B
+0.20%+0.57%+54.34%+72.51% 239B
+2.18%+4.78%-15.17%-52.80% 207B
+0.42%+1.03%+32.74%+95.19% 186B
Average +0.76%-0.70%+30.06%+52.75% 410.37B
Weighted average by Cap. +0.51%-0.84%+38.79%+68.03%

Financials

2026 *2027 *
Net sales 62.64B 77.08B 66.5B 57.08B 107B 7,282B 107B 742B 288B 3,723B 289B 283B 12,230B 65.47B 80.56B 69.5B 59.65B 111B 7,610B 112B 775B 301B 3,891B 303B 296B 12,781B
Net income 14.51B 17.85B 15.4B 13.22B 24.7B 1,686B 24.89B 172B 66.65B 862B 67.03B 65.56B 2,832B 16.33B 20.1B 17.34B 14.88B 27.81B 1,898B 28.02B 193B 75.04B 971B 75.47B 73.82B 3,188B
Net Debt 10.87B 13.37B 11.54B 9.9B 18.51B 1,263B 18.64B 129B 49.93B 646B 50.21B 49.11B 2,121B 4.02B 4.95B 4.27B 3.66B 6.85B 467B 6.9B 47.59B 18.47B 239B 18.57B 18.17B 785B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA